208 related articles for article (PubMed ID: 14728064)
1. Hyperuricemia and adverse outcomes in cardiovascular disease: potential for therapeutic intervention.
Gavin AR; Struthers AD
Am J Cardiovasc Drugs; 2003; 3(5):309-14. PubMed ID: 14728064
[TBL] [Abstract][Full Text] [Related]
2. Allopurinol as a therapeutic option in cardiovascular disease.
Okafor ON; Farrington K; Gorog DA
Pharmacol Ther; 2017 Apr; 172():139-150. PubMed ID: 27916655
[TBL] [Abstract][Full Text] [Related]
3. Uric acid lowering therapy in cardiovascular diseases.
Volterrani M; Iellamo F; Sposato B; Romeo F
Int J Cardiol; 2016 Jun; 213():20-2. PubMed ID: 26386814
[TBL] [Abstract][Full Text] [Related]
4. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
Kohagura K; Tana T; Higa A; Yamazato M; Ishida A; Nagahama K; Sakima A; Iseki K; Ohya Y
Hypertens Res; 2016 Aug; 39(8):593-7. PubMed ID: 27075830
[TBL] [Abstract][Full Text] [Related]
5. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
Oyama J; Tanaka A; Sato Y; Tomiyama H; Sata M; Ishizu T; Taguchi I; Kuroyanagi T; Teragawa H; Ishizaka N; Kanzaki Y; Ohishi M; Eguchi K; Higashi Y; Yamada H; Maemura K; Ako J; Bando YK; Ueda S; Inoue T; Murohara T; Node K;
Cardiovasc Diabetol; 2016 Jun; 15():87. PubMed ID: 27317093
[TBL] [Abstract][Full Text] [Related]
7. Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
Schuchardt M; Herrmann J; Tolle M; van der Giet M
Curr Pharm Des; 2017; 23(23):3391-3404. PubMed ID: 28413972
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
Bove M; Cicero AFG; Borghi C
Curr Hypertens Rep; 2017 Oct; 19(12):95. PubMed ID: 29071435
[TBL] [Abstract][Full Text] [Related]
9. Hyperuricemia and cardiovascular disease risk.
Borghi C; Verardi FM; Pareo I; Bentivenga C; Cicero AF
Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1219-25. PubMed ID: 25192804
[TBL] [Abstract][Full Text] [Related]
10. Administration of procyanidins from grape seeds reduces serum uric acid levels and decreases hepatic xanthine dehydrogenase/oxidase activities in oxonate-treated mice.
Wang Y; Zhu JX; Kong LD; Yang C; Cheng CH; Zhang X
Basic Clin Pharmacol Toxicol; 2004 May; 94(5):232-7. PubMed ID: 15125693
[TBL] [Abstract][Full Text] [Related]
11. [The role of uric acid and allopurinol therapy in cardiovascular disease].
Linhart A; Rob D
Vnitr Lek; 2015 May; 61(5):421-30. PubMed ID: 26075851
[TBL] [Abstract][Full Text] [Related]
12. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
13. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition.
Harzand A; Tamariz L; Hare JM
Congest Heart Fail; 2012; 18(3):179-82. PubMed ID: 22587748
[TBL] [Abstract][Full Text] [Related]
14. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
Bove M; Cicero AF; Veronesi M; Borghi C
Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818
[TBL] [Abstract][Full Text] [Related]
15. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
16. Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.
Borghi C; Palazzuoli A; Landolfo M; Cosentino E
Heart Fail Rev; 2020 Jan; 25(1):43-51. PubMed ID: 31745840
[TBL] [Abstract][Full Text] [Related]
17. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
Siu YP; Leung KT; Tong MK; Kwan TH
Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
[TBL] [Abstract][Full Text] [Related]
18. [Secondary hyperuricemia in hematologic disease].
Inai K; Tsutani H
Nihon Rinsho; 2003 Jan; 61 Suppl 1():299-303. PubMed ID: 12629735
[No Abstract] [Full Text] [Related]
19. Synthesis and evaluation of hydroxychalcones as multifunctional non-purine xanthine oxidase inhibitors for the treatment of hyperuricemia.
Xie Z; Luo X; Zou Z; Zhang X; Huang F; Li R; Liao S; Liu Y
Bioorg Med Chem Lett; 2017 Aug; 27(15):3602-3606. PubMed ID: 28655421
[TBL] [Abstract][Full Text] [Related]
20. Phytochemicals from Acacia confusa heartwood extracts reduce serum uric acid levels in oxonate-induced mice: their potential use as xanthine oxidase inhibitors.
Tung YT; Hsu CA; Chen CS; Yang SC; Huang CC; Chang ST
J Agric Food Chem; 2010 Sep; 58(18):9936-41. PubMed ID: 20806936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
